Latest News and Press Releases

CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- A recent round of open-market purchases marks another display of confidence as the small molecule telomere-targeting cancer therapy by MAIA Biotechnology,...

CHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology (NYSE American: MAIA) – The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a...

OTC:LMMY Dr. Marvin Hausman, an esteemed Immunologist and Board-Certified Urological Surgeon. With more than five decades of experience in drug research.

LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) announced the completion of the acquisition of 100% of Exousia AI, Inc. in an all-stock transaction.

LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) announced the completion of the acquisition of 100% of Exousia AI, Inc. in an all-stock transaction.

Partial remissions and complete metabolic responses in PD-1/PD-L1-resistant cancersFirst-in-class multi-checkpoint inhibitor with robust efficacy and safetyCombination arm with pembrolizumab...

Recognition highlights company’s antithrombotic platform and late-stage programs designed to transform care in oncology and inflammation driven diseases

GAITHERSBURG, Md., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty...

GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty...

Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells  CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA)...